Decrypting the role of Cripto in tumorigenesis

Journal of Clinical Investigation

Volumn 112, Issue 4, 2003, Pages 500-502

  Shen, Michael M ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; CELL PROTEIN; CELL SURFACE ASSOCIATED PROTEIN; CRIPTO PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN NODAL; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR; MEMBRANE PROTEIN; TDGF1 PROTEIN, HUMAN; TUMOR PROTEIN;

BINDING AFFINITY; CARCINOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CELL DIVISION; HUMAN; METABOLISM; NEOPLASM; NOTE; PHYSIOLOGY; PROTEIN MOTIF;

ACTIVINS; AMINO ACID MOTIFS; ANIMALS; CELL DIVISION; EPIDERMAL GROWTH FACTOR; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 85047692622     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI19546     Document Type: Review

References (18)

1. Adkins, H.B., et al. 2003. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J. Clin. Invest. 112:575-587. doi:10.1172/JCI200317788.
2. Ciccodicola, A., et al. 1989. Molecular characterization of a gene of the "EGF family" expressed in undifferentiated human NTERA2 teratocarcinoma cells. EMBO J. 8:1987-1991.
3. Shen, M.M., and Schier, A.F. 2000. The EGF-CFC gene family in vertebrate development. Trends Genet. 16:303-309.
4. Whitman, M. 2001. Nodal signaling in early vertebrate embryos. Themes and variations. Dev. Cell. 1:605-617.
5. Yeo, C., and Whitman, M. 2001. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol. Cell. 7:949-957.
6. Yan, Y.T., et al. 2002. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol. Cell. Biol. 22:4439-4449.
7. Schiffer, S.G., et al. 2001. Fucosylation of Cripto is required for its ability to facilitate nodal signaling. J. Biol. Chem. 276:37769-37778.
8. Kumar, A., et al. 2001. Nodal signaling uses activin and transforming growth factor-beta receptor-regulated Smads. J. Biol. Chem. 276:656-661.
9. Salomon, D.S., et al. 2000. The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr. Relat. Cancer. 7:199-226.
10. Ciardiello, F., Dono, R., Kim, N., Persico, M.G., and Salomon, D.S. 1991. Expression of cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. Cancer Res. 51:1051-1054.
11. Ciardiello, F., et al. 1994. Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene. 9:291-298.
12. Gray, P.C., Harrison, C.A., and Vale, W. 2003. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc. Natl. Acad. Sci. U. S. A. 100:5193-5198.
13. Lewis, K.A., et al. 2000. Betaglycan binds inhibin and can mediate functional antagonism of activin signaling. Nature. 404:411-414.
14. Bianco, C., et al. 2002. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial cells. Mol. Cell Biol. 22:2586-2597.
15. Cheng, S.K., Olale, F., Bennert, J.T., Brivanlou, A.H., and Schier, A.F. 2003. EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev. 17:31-36.
16. Ebert, A.D., et al. 1999. Cripto-1 induces phosphatidylinositol 3′-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3β in human cervical carcinoma cells. Cancer Res 59:4502-4505.
17. Bianco, C., et al. 2003. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res. 63:1192-1197.
18. Derynck, R., Akhurst, R.J., and Balmain, A. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29:117-129.